Valencia, Calif. — April 9, 2026 — Bioness Medical, Inc. (“Bioness”, or the “Company”), a
global leader in functional electrical stimulation (FES) and advanced rehabilitation
technologies, today announced the acquisition of the PoNS® (Portable Neuromodulation
Stimulator) System product line. This strategic addition expands Bioness Medical’s
capabilities into non-invasive central neuromodulation and reinforces its position as a
comprehensive provider of solutions for patients with gait and balance disorders
resulting from neurological injury or disease.
For nearly 20 years, Bioness has focused on functional electrical stimulation targeting
affected limbs to improve mobility and function following stroke, traumatic brain injury,
multiple sclerosis, cerebral palsy, and other neurological conditions. The addition of the
PoNS System expands the Company’s platform to include non-invasive
neuromodulation delivered via the tongue, stimulating cranial nerve pathways to
promote neuroplasticity and functional recovery.
The PoNS System has been studied in patients with chronic neurological conditions,
demonstrating improvements in gait and balance when used as part of a supervised
rehabilitation program.
Advancing the Future of Neurorehabilitation
“PoNS technology represents a differentiated approach to neuromodulation that
complements our core FES platform,” said Todd Cushman, Chief Executive Officer of
Bioness Medical. “Bioness has built deep relationships with rehabilitation providers over
decades. With PoNS, we expand beyond peripheral stimulation into central
neuromodulation—offering clinicians a non-invasive therapy that engages neural
pathways involved in balance and gait. This positions Bioness to deliver more
comprehensive, multi-modal rehabilitation solutions to patients.”
Expanding a Multi-Modal Therapy Platform
The acquisition brings together complementary technology platforms:
• Bioness Medical’s established portfolio, including L300 Go®, H200® Wireless, and
Vector® Gait & Safety System
• PoNS® neuromodulation therapy, designed to promote neuroplasticity through noninvasive cranial nerve stimulation via the tongue
Together, these technologies enable clinicians to address both peripheral motor
activation and central neural network modulation within a unified rehabilitation
approach.
Strengthening Clinical and Commercial Capabilities
The acquisition enhances Bioness Medical’s research and development capabilities and
supports expanded clinical programs, including combination therapy approaches
integrating FES and neuromodulation.
This acquisition also expands Bioness Medical’s addressable market within the rapidly
growing neuromodulation and neurorehabilitation sectors, positioning the Company for
continued growth across both clinical and commercial channels.
The PoNS System product line marks Bioness Medical’s third acquisition since
becoming an independent neurorehabilitation company following its acquisition by
Accelmed Partners (“Accelmed”) on December 31, 2024. The Company continues to
expand its portfolio through targeted strategic initiatives and organic innovation.